Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
about
Immunoglobulin for preventing respiratory syncytial virus infectionEntry of parainfluenza virus into cells as a target for interrupting childhood respiratory diseasePassive immunity in prevention and treatment of infectious diseasesRespiratory viruses other than influenza virus: impact and therapeutic advancesThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinStructural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersAnalysis of Human RSV Immunity at the Molecular Level: Learning from the Past and PresentPotent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerasesUse of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Passive immunization against HIV/AIDS by antibody gene transfer.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsA peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus.A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infectionCost effectiveness of palivizumab in Spain: an analysis using observational data.Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentManagement of acute bronchiolitisProtection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Effects of aging on the adaptive immune response to respiratory virus infections.Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirusIntranasal antibody prophylaxis for protection against viral disease.Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.Active and passive immunisation against respiratory syncytial virus.RSV infection in infants and young children. What's new in diagnosis, treatment, and prevention?Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.Viral lower respiratory tract infection in infants and young children.Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.Immunoglobulin for preventing respiratory syncytial virus infection.A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.Respiratory syncytial virus infection in adults
P2860
Q24245599-B0340A6C-D88F-4DBD-A8B2-66CF0658DF79Q24530163-E4A5262C-D5FF-4F23-93F4-4265277B49A0Q24550699-6B301351-5C0C-4584-A6A2-439AA571A86EQ24655957-EF1CB442-B6C3-479A-BFC4-64F6F13AB79BQ26864494-D7C40144-6A81-4AA9-A587-519C3E753BA9Q27469855-5F940CD9-D146-4949-AE1B-88957EF8A72DQ27485318-6292F7B0-A4B4-49D1-8BA2-968DFB18E1D2Q27667876-F3903F99-A859-4A1E-8DA5-D3AACC06B2DDQ28080556-12E237D9-EC60-4AB6-803F-85E75671A88AQ28478155-DBAE5C92-8BF7-44DF-90BA-E65ECCF6279DQ30145641-254C8DA1-BC48-48CF-B337-C1E4A6ADA10CQ30240274-37A1CAF8-E638-46A9-B364-A186C02B27E5Q30358434-B5493140-80C7-4DE5-BACB-C226B75B058CQ30431941-30D6422A-C5E0-4E1D-9FBA-EF10CB770062Q31047460-60F3575C-6190-46DB-8AC6-74BB7A9E14C2Q32099239-6F97B229-FDEC-4EA1-B705-1C179809F47EQ33409160-43650C54-C185-420B-B5A2-0FEF24BD02B2Q33478019-6431D200-91F4-4481-9484-FA07BE285238Q33517462-FC2548BA-662D-4BAE-A910-C0465342ABD7Q33588916-30BB162B-BA71-404E-A228-E6669437518AQ33625250-C4ECFA44-B0A3-4EC8-846F-ECFC5F722A02Q33647300-0B558BA0-DB00-4983-88AE-570126F7900CQ33655089-37B6D014-332D-4CAD-B57F-1DF99D394F60Q33678943-C4DACA25-F58A-4BEA-974B-3F03BB9375C3Q33683058-5DA3F2E1-918B-4355-BC32-F9483167367EQ33705088-8E42876B-813C-4836-8A68-F28531ABF0F4Q33723350-1E119BE9-245E-484F-BFFB-9EF59B0D3765Q33724997-924A2156-59EC-428C-82B7-D0B18C2959D7Q33782181-6224B622-C921-46ED-BFE4-51246A96045CQ33782438-5F3E6589-F651-445A-8584-4D20C9EC2430Q33802570-553D0D76-F011-4B30-AE63-092CD19D42D2Q33809443-5D03BA17-B801-4EF5-9A22-9F63B3E101FBQ33815412-13BDA608-E4B3-40D0-AA53-B6608163F9EAQ33815604-BCDE0B33-9985-4C45-A72C-6A71BE14E6B0Q33836560-5DC06277-7945-447E-B61C-E4763276B162Q33849224-073A9646-C16C-48C1-BB75-67437EFB0F21Q33870586-4E9E7CC0-8A20-4D38-BAF2-95F902CC9530Q33909278-15863DDC-1031-40B4-B6FB-2246C566977FQ33936520-67F69BD2-CE74-475D-94D5-D4567E18933EQ33961877-F1EA6047-62E3-402F-9750-7CA3B91C1431
P2860
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Prophylactic administration of ...... s Immune Globulin Study Group.
@ast
Prophylactic administration of ...... s Immune Globulin Study Group.
@en
Prophylactic administration of ...... s Immune Globulin Study Group.
@nl
type
label
Prophylactic administration of ...... s Immune Globulin Study Group.
@ast
Prophylactic administration of ...... s Immune Globulin Study Group.
@en
Prophylactic administration of ...... s Immune Globulin Study Group.
@nl
prefLabel
Prophylactic administration of ...... s Immune Globulin Study Group.
@ast
Prophylactic administration of ...... s Immune Globulin Study Group.
@en
Prophylactic administration of ...... s Immune Globulin Study Group.
@nl
P2093
P1476
Prophylactic administration of ...... s Immune Globulin Study Group.
@en
P2093
Groothuis JR
Meissner HC
Rodriguez WJ
Welliver RC
P304
P356
10.1056/NEJM199311183292102
P407
P577
1993-11-01T00:00:00Z